恩格列净对2型糖尿病或糖尿病前期合并射血分数降低心衰患者左心室容积的影响(SUGAR-DM-HF研究)
SUGAR-DM-HF是一项多中心随机双盲安慰剂对照试验,纳入105例NYHA II-IV级、LVEF≤40%且合并2型糖尿病或糖尿病前期的HFrEF患者,随机接受恩格列净10mg每日一次或安慰剂治疗36周。结果显示恩格列净显著降低LV收缩末期容积指数6.0 mL/m2(95%CI -10.8至-1.2,P=0.015)和舒张末期容积指数8.2 mL/m2(95%CI -13.7至-2.6,P=0.0042),并降低NT-proBNP 28%(2%-47%,P=0.038),但LV整体纵向应变无差异。
要点
- 恩格列净降低HFrEF合并糖尿病/糖尿病前期患者LV收缩末期和舒张末期容积指数。
- 恩格列净降低NT-proBNP 28%,提示有利的逆重构可能介导心衰获益。
- LV整体纵向应变、利尿剂强化、症状评分、6分钟步行距离及B线无组间差异。
核心结论
- 在HFrEF合并2型糖尿病或糖尿病前期患者中,恩格列净降低左心室容积,有利的逆重构可能是SGLT2抑制剂减少心衰住院和死亡的机制之一。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照试验(SUGAR-DM-HF),纳入105例NYHA II-IV级、LVEF≤40%且合并2型糖尿病或糖尿病前期的HFrEF患者,1:1随机接受恩格列净10mg每日一次或安慰剂,按年龄(<65和≥65岁)和血糖状态分层,随访36周。
主要发现
- 恩格列净较安慰剂降低LV收缩末期容积指数6.0(95%CI -10.8至-1.2)mL/m2,P=0.015。
- 恩格列净较安慰剂降低LV舒张末期容积指数8.2(95%CI -13.7至-2.6)mL/m2,P=0.0042。
- 恩格列净较安慰剂降低NT-proBNP 28%(2%-47%),P=0.038。
- LV整体纵向应变、其他心脏磁共振指标、利尿剂强化、KCCQ总症状评分、6分钟步行距离及肺超声B线均无组间差异。
临床怎么用
- 对于HFrEF合并2型糖尿病或糖尿病前期的患者,恩格列净可考虑用于促进左心室逆重构。
- 恩格列净降低LV容积和NT-proBNP的效应支持其作为该人群标准治疗的一部分。
局限性
- 样本量较小(105例),随访时间较短(36周)。
- 研究仅纳入合并2型糖尿病或糖尿病前期的HFrEF患者,结果外推至无糖代谢异常人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sodium-glucose cotransporter 2 inhibitors reduce the risk of heart failure hospitalization and cardiovascular death in patients with heart failure and reduced ejection fraction (HFrEF). However, their effects on cardiac structure and function in HFrEF are uncertain. METHODS: We designed a multicenter, randomized, double-blind, placebo-controlled trial (the SUGAR-DM-HF trial [Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects in Patients With Diabetes Mellitus, or Prediabetes, and Heart Failure]) to investigate the cardiac effects of empagliflozin in patients in New York Heart Association functional class II to IV with a left ventricular (LV) ejection fraction ≤40% and type 2 diabetes or prediabetes. Patients were randomly assigned 1:1 to empagliflozin 10 mg once daily or placebo, stratified by age (<65 and ≥65 years) and glycemic status (diabetes or prediabetes). The coprimary outcomes were change from baseline to 36 weeks in LV end-systolic volume indexed to body surface area and LV global longitudinal strain both measured using cardiovascular magnetic resonance. Secondary efficacy outcomes included other cardiovascular magnetic resonance measures (LV end-diastolic volume index, LV ejection fraction), diuretic intensification, symptoms (Kansas City Cardiomyopathy Questionnaire Total Symptom Score, 6-minute walk distance, B-lines on lung ultrasound, and biomarkers (including N-terminal pro-B-type natriuretic peptide). RESULTS: From April 2018 to August 2019, 105 patients were randomly assigned: mean age 68.7 (SD, 11.1) years, 77 (73.3%) male, 82 (78.1%) diabetes and 23 (21.9%) prediabetes, mean LV ejection fraction 32.5% (9.8%), and 81 (77.1%) New York Heart Association II and 24 (22.9%) New York Heart Association III. Patients received standard treatment for HFrEF. In comparison with placebo, empagliflozin reduced LV end-systolic volume index by 6.0 (95% CI, -10.8 to -1.2) mL/m2 (P=0.015). There was no difference in LV global longitudinal strain. Empagliflozin reduced LV end-diastolic volume index by 8.2 (95% CI, -13.7 to -2.6) mL/m2 (P=0.0042) and reduced N-terminal pro-B-type natriuretic peptide by 28% (2%-47%), P=0.038. There were no between-group differences in other cardiovascular magnetic resonance measures, diuretic intensification, Kansas City Cardiomyopathy Questionnaire Total Symptom Score, 6-minute walk distance, or B-lines. CONCLUSIONS: The sodium-glucose cotransporter 2 inhibitor empagliflozin reduced LV volumes in patients with HFrEF and type 2 diabetes or prediabetes. Favorable reverse LV remodeling may be a mechanism by which sodium-glucose cotransporter 2 inhibitors reduce heart failure hospitalization and mortality in HFrEF. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT03485092.
引用
- Lee MMY, Brooksbank KJM, Wetherall K, et al. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF). Circulation. 2020. PMID: 33186500. doi:10.1161/CIRCULATIONAHA.120.052186
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。